Our findings align with previous meta-analysis that demonstrated a lower risk of HHF, CV death and all-cause mortality in T2DM patients with HF who received SGLT2 inhibitors [66, 67] and confirmed that the clinical benefits of SGLT2 inhibitors on CV outcomes extend to older and frail HF patients with T2DM. This evidence concerns the gene SLC5A2 and hydrops fetalis.